For the quarter ending 2025-09-30, CRDF made $120,000 in revenue. -$11,264,000 in net income. Net profit margin of -9386.67%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Royalty revenues | 120,000 | 121,000 | 109,000 | 177,500 |
| Research and development | 8,197,000 | 11,580,000 | 10,477,000 | 8,859,500 |
| Selling, general and administrative | 3,897,000 | 3,318,000 | 4,014,000 | 3,070,500 |
| Total operating expenses | 12,094,000 | 14,898,000 | 14,491,000 | 11,930,000 |
| Loss from operations | -11,974,000 | -14,777,000 | -14,382,000 | -11,752,500 |
| Interest income, net | 716,000 | 835,000 | 941,000 | 856,500 |
| Other income (expense), net | 0 | -1,000 | 7,000 | -3,000 |
| Total other income (expense), net | 716,000 | 834,000 | 948,000 | 853,500 |
| Net loss | -11,258,000 | -13,943,000 | -13,434,000 | -10,899,000 |
| Preferred stock dividend payable on series a convertible preferred stock | 6,000 | 6,000 | 6,000 | 6,000 |
| Net loss attributable to common stockholders | -11,264,000 | -13,949,000 | -13,440,000 | -10,905,000 |
| Earnings per share, basic | -0.17 | -0.21 | -0.2 | -0.22 |
| Earnings per share, diluted | -0.17 | -0.21 | -0.2 | -0.22 |
| Weighted average number of shares outstanding, basic | 66,879,000 | 66,526,000 | 66,524,000 | -22,020,000 |
| Weighted average number of shares outstanding, diluted | 66,879,000 | 66,526,000 | 66,524,000 | -22,020,000 |
Cardiff Oncology, Inc. (CRDF)
Cardiff Oncology, Inc. (CRDF)